Tag

Novartis

All articles tagged with #novartis

business15 days ago•5 min saved

Novartis to acquire Excellergy to accelerate next-gen anti-IgE therapy

Novartis will acquire Excellergy for up to USD 2 billion in upfront and milestone payments to bolster its immunology portfolio with Exl-111, a Phase 1, half-life–extended anti-IgE antibody designed to dissociate receptor-bound IgE and drive faster, deeper IgE signaling suppression. If approved, Exl-111 could improve symptom control and dosing convenience across IgE‑driven diseases such as food allergy, chronic urticaria, inducible urticaria and asthma; closing is targeted for H2 2026, subject to regulatory approvals.

via Novartis|

#allergy #anti-ige #business

business22 days ago•5 min saved

Novartis bets on mutant PI3Kα with SNV4818 acquisition to sharpen breast cancer pipeline

Novartis today announced plans to acquire SNV4818 from Synnovation Therapeutics' Pikavation subsidiary for up to USD 3 billion (USD 2 billion upfront with up to USD 1 billion in milestones) to advance a pan-mutant‑selective PI3Kα inhibitor in HR+/HER2- breast cancer; SNV4818 is designed to target mutant PI3Kα (PIK3CA) while sparing wild-type PI3Kα to improve tolerability and enable combination with hormonal therapies, addressing an unmet need in roughly 40% of HR+/HER2- patients; closing is expected in the first half of 2026.

via Novartis|

#acquisition #business #hrher2

culture1 month ago•10 min saved

Lacks Estate Secures Another Win in HeLa Cell Justice Battle

Henrietta Lacks’ estate has scored another legal win in the decades-long fight over the unauthorized use of her immortal HeLa cells, with recent settlements against major pharma firms following earlier deals (including Thermo Fisher) and ongoing discussions about patient consent and exploitation in medical research.

via The Root|

#bioethics #culture #hela-cells

business1 month ago•2 min saved

Atrium Therapeutics spins out from Novartis-Avidity deal with two cardio RNA therapies

Atrium Therapeutics, a spinout formed from Novartis's $12 billion acquisition of Avidity Biosciences, debuts with $270 million in cash and two preclinical RNA interference assets (ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy). Led by Kathleen Gallagher, Atrium plans a Phase 1 trial for ATR 1072 in the second half of this year and for ATR 1086 in 2027, with the new ticker RNAM, inheriting Avidity's market position.

via Fierce Biotech|

#atrium-therapeutics #avidity-biosciences #business

health1 month ago•3 min saved

Lacks Family Reaches Confidential Pact With Novartis Over HeLa Cells

The family of Henrietta Lacks has reached a second confidential settlement with Novartis over profits from her immortal HeLa cells, continuing a long fight for compensation; terms are undisclosed and follow a prior settlement with Thermo Fisher, underscoring ongoing ethical questions about consent and the benefits derived from her cells.

via BBC|

#bioethics #health #hela

health1 month ago•14 min saved

Novartis settles with Lacks family over HeLa cell legacy

Novartis has reached a settlement with Henrietta Lacks' estate over the use of her HeLa cells in medical research, ending a dispute with undisclosed terms; the case highlights ongoing debates about consent and compensation tied to the iconic cell line used in biomedical advances since 1951.

via AP News|

#bioethics #health #hela

health2 months ago•8 min saved

Global push to end leprosy gains momentum ahead of World Leprosy Day

WHO renews its commitment to a leprosy-free world ahead of World Leprosy Day, highlighting free multidrug therapy and post-exposure prophylaxis, a 25-year partnership with novartis, and ongoing anti-stigma efforts, while noting 172,717 new cases in 2024 across 188 reporting areas.

via World Health Organization (WHO)|

#global-health-partnerships #health #leprosy

business2 months ago•3 min saved

Tariffs Tighten Markets as Dalio, Jassy, Narasimhan Speak

A Seeking Alpha roundup features Ray Dalio warning that Trump's aggressive foreign policy could deter foreign investors from U.S. assets, Amazon noting tariffs are lifting some prices and slowing inventory turnover, and Novartis stating its U.S. investments and trade deals should shield it from most tariffs with contingency plans in place.

via Seeking Alpha|

#amazon #business #markets

business5 months ago•0 min saved

Novartis's $12B Avidity Deal Boosts Biotech Stocks and Neuroscience Pipeline

Novartis' CEO indicated that their $12 billion acquisition of Avidity BioSciences could have been twice as large, highlighting the significance of timing in deal-making.

via Endpoints News|

#acquisition #avidity-biosciences #biotech

business5 months ago•3 min saved

Novartis Nears $12 Billion Deal to Acquire Avidity Biosciences

Novartis is acquiring Avidity Biosciences for about $12 billion to expand its portfolio in rare muscle disorders and strengthen its US presence, with Avidity's early-stage cardiology programs to be spun off into a new company, Spinco.

via Reuters|

#acquisition #avidity-biosciences #biotech

business5 months ago•11 min saved

Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Neuroscience Pipeline

Novartis plans to acquire Avidity Biosciences for $12 billion to strengthen its neuroscience pipeline with late-stage RNA therapeutics targeting neuromuscular diseases, including a new platform for muscle-directed delivery of RNA therapies, aiming for product launches before 2030 and increasing its sales growth forecast to 6% CAGR for 2024-2029.

via Novartis|

#acquisition #avidity-biosciences #business

business5 months ago•1 min saved

Novartis Approaches $12 Billion Acquisition of Avidity Biosciences

Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.

via Financial Times|

#acquisition #avidity-biosciences #business

business5 months ago•1 min saved

Novartis to Acquire Avidity Biosciences for $12 Billion in Cash

Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.

via CNBC|

#acquisition #avidity-biosciences #biotech

business5 months ago•1 min saved

Novartis Nears $10 Billion Deal to Acquire Avidity Biosciences

Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.

via Bloomberg.com|

#avidity-biosciences #biotechnology #business

healthcare6 months ago•8 min saved

Novartis' Remibrutinib Gains FDA Approval for Chronic Spontaneous Urticaria

Novartis received FDA approval for Rhapsido (remibrutinib), the first oral BTK inhibitor for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamines, offering a new, fast-acting, and safe treatment option without the need for injections or lab monitoring.

via Novartis|

#chronic-spontaneous-urticaria #fda-approval #healthcare